• Dr. Devavrat Arya

Senior Consultant – Principal Consultant, Medical Oncology, Max Hospital, Saket Total years of Experience - Over 15 years

Trained at – MBBS (Maulana Azad Med. College, Delhi), MD Internal Medicine (Govt. Medical College, Surat), DM Medical Oncology (Gujarat Cancer & Research Institute, B J Medical College, Ahmedabad)

About Dr. Devavrat Arya

Dr. Devavrat is a practicing medical oncologist at Max Hospital, Saket wherein he is also a co-guide for DNB postgraduates in Medical Oncology program. He has previously been associated as a Senior Consultant, Medical Oncology with International Oncology Services Private Limited, International Oncology Centre, Fortis Hospital, Noida and as an Hon. Associate Consultant, Medical Oncology, Action Cancer Hospital, Delhi. His position as a Principal consultant in medical oncology requires decision making, clinical care and treatment of cancer patients with administration of Chemotherapy, Targeted therapies and Immunotherapies to Adult patients with Solid tumors, Hematological malignancies and pediatric cancer patients. In addition to this, he is also a principal investigator in many ongoing (and past) trials such as Evaluation of a Biosimilar Rituximab in Low Grade NHL, Evaluation of a Biosimilar Bevacizumab in Advanced NSCLC Lung, Evaluation of BRCA1/2 mutations in Epithelial Ovarian Cancer, etc.

Dr. Devavrat is an avid researcher and has several publications and presentations to his credit (both national and international) such as a presentation on Molecular Markers including S VEGF as predictive factors in response to anthracycline based neo adjuvant chemotherapy in patients with Locally Advanced Breast Cancer at the IMPAKT breast cancer conference in Belgium (2012), Molecular Markers as prognostic factors and response to anthracycline based chemotherapy in patients with Locally Advanced Breast Cancer – Experiences from a developing nation, which was accepted for publication in abstract book, in ESMO congress, Vienna (2012), co-author of Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic castration-naive prostate cancer in South Asian population at ASCO (2019), among many more.

Dr. Devavrat was awarded the ESMO Certificate after successfully passing the ESMO in 2011. He has also been part of international conferences such as the Asia Pacific Immuno-oncology meet, Hong Kong (2017), the ESMO congress (2018), the annual conference of Multinational Association for Supportive Care in Cancer, Vienna (2018), and many more. His key areas of interest are Breast Cancer, Bone & Soft Tissue Sarcoma, Head & Neck Cancers and Gynaecological Malignancies and holds a membership of several prestigious bodies like Indian Society of Medical and Paediatric Oncology, European Society of Medical Oncology, and more.